Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | NPR3 | P17342 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 4/20 | 0.47 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27719027 | 1.00 | PPARG (0.54) | PPARGPPARANPR3MMENPSR1 | |
| SCHEMBL29377546 | 0.89 | PPARG (0.51) | PPARGPPARANPR3MMENAALAD2 | |
| SCHEMBL15583227 | 0.86 | NPR3 (0.59) | NPR3MMENPSR1NAALAD2CYP1A2 | |
| SCHEMBL5939842 | 0.84 | L3MBTL1 (0.59) | MMENPSR1NAALAD2L3MBTL1 | |
| SCHEMBL5939834 | 0.84 | L3MBTL1 (0.59) | MMENPSR1NAALAD2L3MBTL1 | |
| SCHEMBL4195980 | 0.79 | L3MBTL1 (0.53) | NPR3L3MBTL1 | |
| SCHEMBL4195984 | 0.79 | L3MBTL1 (0.53) | NPR3L3MBTL1 | |
| SCHEMBL1533647 | 0.79 | PPARG (0.58) | PPARGMMENPSR1NAALAD2CYP1A2 | |
| SCHEMBL6250861 | 0.79 | PPARG (0.58) | PPARGMMENPSR1NAALAD2CYP1A2 | |
| SCHEMBL1533645 | 0.79 | PPARG (0.58) | PPARGMMENPSR1NAALAD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881982-B1 | IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS | ELAN PHARM INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8030328-B2 | Imidazolone phenylalanine derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| EP-1881982-A1 | IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS | Elan Pharmaceuticals Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | TBD | 2007-02-15 | — | — | US | disclosed |
| WO-2006127584-A1 | IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | VCAM1, ICAM1, IL4I1 | PPARG 3837/4885PPARA 2482/4885NPR3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.